beta-alanine has been researched along with Kidney Diseases in 15 studies
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established." | 7.81 | Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. ( Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R, 2015) |
| "A 65-year-old man, who had been treated with dabigatran for 66 days prior to electrical cardioversion, developed extensive intestinal, renal and cerebral thromboembolism five days after cardioversion." | 7.79 | [Extensive thromboembolism after cardioversion in a patient treated with dabigatran]. ( Buch, TN; Holm, J; Munck, LK, 2013) |
| "Dabigatran, administered orally as the prodrug dabigatran etexilate (DE), is a direct thrombin inhibitor shown to be effective in the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF)." | 7.78 | Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. ( Clemens, A; Friedman, J; Haertter, S; Lehr, T; Liesenfeld, KH; Reilly, PA; Staab, A, 2012) |
| "The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established." | 3.81 | Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. ( Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R, 2015) |
| "A 65-year-old man, who had been treated with dabigatran for 66 days prior to electrical cardioversion, developed extensive intestinal, renal and cerebral thromboembolism five days after cardioversion." | 3.79 | [Extensive thromboembolism after cardioversion in a patient treated with dabigatran]. ( Buch, TN; Holm, J; Munck, LK, 2013) |
| "Dabigatran, administered orally as the prodrug dabigatran etexilate (DE), is a direct thrombin inhibitor shown to be effective in the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF)." | 3.78 | Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. ( Clemens, A; Friedman, J; Haertter, S; Lehr, T; Liesenfeld, KH; Reilly, PA; Staab, A, 2012) |
| "The objective of this work was to derive a dosing regimen for dabigatran in patients with severe renal impairment by modeling and simulation." | 2.77 | Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. ( Hariharan, S; Madabushi, R, 2012) |
| " In contrast to warfarin, most NOACs need dosage adjustments in renal impairment and are contraindicated in severe liver impairment, and there are no specific antidotes for treating NOAC-related over-anticoagulation." | 2.50 | New oral anticoagulants in practice: pharmacological and practical considerations. ( Bajorek, B; Wang, Y, 2014) |
| "Dabigatran is an oral direct thrombin inhibitor widely used to prevent and treat various thromboembolic complications." | 2.49 | Dabigatran and kidney disease: a bad combination. ( Berns, JS; Chaknos, CM; Knauf, F; Perazella, MA, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, L | 1 |
| Liu, F | 1 |
| Guan, Y | 1 |
| Zou, J | 1 |
| Zhang, C | 1 |
| Xiong, C | 1 |
| Zhao, TC | 1 |
| Bayliss, G | 1 |
| Li, X | 1 |
| Zhuang, S | 1 |
| Buch, TN | 1 |
| Holm, J | 1 |
| Munck, LK | 1 |
| Knauf, F | 1 |
| Chaknos, CM | 1 |
| Berns, JS | 1 |
| Perazella, MA | 1 |
| Wang, Y | 1 |
| Bajorek, B | 1 |
| Tran, H | 1 |
| Joseph, J | 1 |
| Young, L | 1 |
| McRae, S | 1 |
| Curnow, J | 1 |
| Nandurkar, H | 1 |
| Wood, P | 1 |
| McLintock, C | 1 |
| Graham, DJ | 1 |
| Reichman, ME | 1 |
| Wernecke, M | 1 |
| Zhang, R | 1 |
| Southworth, MR | 1 |
| Levenson, M | 1 |
| Sheu, TC | 1 |
| Mott, K | 1 |
| Goulding, MR | 1 |
| Houstoun, M | 1 |
| MaCurdy, TE | 1 |
| Worrall, C | 1 |
| Kelman, JA | 1 |
| Lane, DA | 1 |
| Wood, K | 1 |
| Kooiman, J | 1 |
| van de Peppel, WR | 1 |
| van der Meer, FJ | 1 |
| Huisman, MV | 1 |
| Lehr, T | 1 |
| Haertter, S | 1 |
| Liesenfeld, KH | 1 |
| Staab, A | 1 |
| Clemens, A | 1 |
| Reilly, PA | 1 |
| Friedman, J | 1 |
| Hariharan, S | 1 |
| Madabushi, R | 1 |
| Lillo-Le Louët, A | 1 |
| Wolf, M | 1 |
| Soufir, L | 1 |
| Galbois, A | 1 |
| Dumenil, AS | 1 |
| Offenstadt, G | 1 |
| Samama, MM | 1 |
| de Gea-García, JH | 1 |
| Alvarez, M | 1 |
| Ruiz-Villa, G | 1 |
| Jiménez-Parra, JD | 1 |
| Klingensmith, WC | 2 |
| Fritzberg, AR | 2 |
| Spitzer, VM | 2 |
| Johnson, DL | 1 |
| Kuni, CC | 2 |
| Williamson, MR | 1 |
| Washer, G | 1 |
| Weil, R | 1 |
| Soini, I | 1 |
| Vorne, M | 1 |
| Karhunen, M | 1 |
| Latteier, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Monitor System for the Safety of Dabigatran Anticoagulation Treatment in Nonvalvular Atrial Fibrillation[NCT02414035] | 1,496 participants (Actual) | Observational | 2015-03-22 | Completed | |||
| Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation[NCT04357288] | 1,200 participants (Anticipated) | Interventional | 2020-12-16 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for beta-alanine and Kidney Diseases
| Article | Year |
|---|---|
Dabigatran and kidney disease: a bad combination.
Topics: Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Coagulation | 2013 |
New oral anticoagulants in practice: pharmacological and practical considerations.
Topics: Administration, Oral; Aging; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comp | 2014 |
1 trial available for beta-alanine and Kidney Diseases
| Article | Year |
|---|---|
Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment.
Topics: Adult; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Computer Simulation; Dabigatran; Female; H | 2012 |
12 other studies available for beta-alanine and Kidney Diseases
| Article | Year |
|---|---|
Critical roles of SMYD2 lysine methyltransferase in mediating renal fibroblast activation and kidney fibrosis.
Topics: Animals; Benzoxazines; beta-Alanine; Cell Proliferation; Epithelial Cells; Epithelial-Mesenchymal Tr | 2021 |
[Extensive thromboembolism after cardioversion in a patient treated with dabigatran].
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Electric Counter | 2013 |
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu | 2014 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles | 2015 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles | 2015 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles | 2015 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles | 2015 |
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindic | 2015 |
Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs.
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biomarkers; Chronic Disease | 2011 |
Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation.
Topics: Antithrombins; Area Under Curve; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Computer Simulat | 2012 |
Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation.
Topics: Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement; Atrial Fibrillation; Benzimidazol | 2012 |
[Wünderlich syndrome in patient anticoagulated with dabigatran].
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia | 2013 |
Clinical evaluation of Tc-99m N,N'-bis(mercaptoacetyl)-2,3-diaminopropanoate as a replacement for I-131 hippurate: concise communication.
Topics: Alanine; beta-Alanine; Computers; Computers, Analog; Hippurates; Humans; Iodine Radioisotopes; Kidne | 1984 |
[New indications of kidney function by gamma imaging].
Topics: Adult; Aged; Aged, 80 and over; Alanine; beta-Alanine; Female; Humans; Iodohippuric Acid; Kidney Dis | 1989 |
Clinical comparison of technetium-99m-N,N-bis(mercaptoacetyl)-2,3-diaminopropanoate with technetium-99m DTPA for renal imaging.
Topics: Alanine; beta-Alanine; Humans; Kidney; Kidney Diseases; Organotechnetium Compounds; Pentetic Acid; R | 1985 |